Pendulum Therapeutics has announced an expanded clinical research collaboration with Mayo Clinic to explore new applications of microbiome-based interventions across women's health and dermatology.

The expanded collaboration builds on a relationship that began in 2013 and reflects the organisations' shared commitment to advancing rigorous, evidence-based microbiome research. The next phase of the collaboration will include new clinical studies led by Mayo Clinic investigators evaluating microbiome-based approaches to support bone health in patients undergoing treatment for breast cancer, as well as research into the gut-skin axis and the role of the microbiome in improving the menopause transition.

These studies will utilise Pendulum's portfolio of microbiome-targeted products and leverage the company's expertise in strain isolation, anaerobic manufacturing, DNA sequencing, and clinical validation.

Colleen Cutcliffe, PhD, Co-founder and CEO, Pendulum Therapeutics, said the collaboration reflects a shared commitment to advancing rigorous microbiome research.

"Our collaboration represents an important milestone in the continued advancement of microbiome science. Together, we are committed to conducting rigorous clinical research that deepens our understanding of how the gut microbiome influences systemic health—from metabolic function to skin health and women's health," said Cutcliffe.

The collaboration builds on Pendulum's more than a decade-long foundation in microbiome research and development. Pendulum is widely recognised for developing Pendulum Glucose Control, the first probiotic clinically shown to reduce A1C in people with type-II diabetes.